These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 36127565)

  • 1. A simulation model estimates lifetime health and economic outcomes of screening prediabetes using the 1-h plasma glucose.
    Andellini M; Manco M; Esposito MT; Tozzi AE; Bergman M; Ritrovato M
    Acta Diabetol; 2023 Jan; 60(1):9-17. PubMed ID: 36127565
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Screening for type 2 diabetes: literature review and economic modelling.
    Waugh N; Scotland G; McNamee P; Gillett M; Brennan A; Goyder E; Williams R; John A
    Health Technol Assess; 2007 May; 11(17):iii-iv, ix-xi, 1-125. PubMed ID: 17462167
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-Effectiveness of a Short Message Service Intervention to Prevent Type 2 Diabetes from Impaired Glucose Tolerance.
    Wong CK; Jiao FF; Siu SC; Fung CS; Fong DY; Wong KW; Yu EY; Lo YY; Lam CL
    J Diabetes Res; 2016; 2016():1219581. PubMed ID: 26798647
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost and clinical implications of diabetes prevention in an Australian setting: a long-term modeling analysis.
    Palmer AJ; Tucker DM
    Prim Care Diabetes; 2012 Jul; 6(2):109-21. PubMed ID: 22153888
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness and cost-utility of insulin glargine compared with NPH insulin based on a 10-year simulation of long-term complications with the Diabetes Mellitus Model in patients with type 2 diabetes in Switzerland.
    Brändle M; Azoulay M; Greiner RA
    Int J Clin Pharmacol Ther; 2007 Apr; 45(4):203-20. PubMed ID: 17474539
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Self-monitoring of blood glucose (SMBG) in patients with type 2 diabetes on oral anti-diabetes drugs: cost-effectiveness in France, Germany, Italy, and Spain.
    Tunis SL; Willis WD; Foos V
    Curr Med Res Opin; 2010 Jan; 26(1):163-75. PubMed ID: 19919377
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The cost-effectiveness analysis of JinQi Jiangtang tablets for the treatment on prediabetes: a randomized, double-blind, placebo-controlled, multicenter design.
    Sun X; Guo L; Shang H; Ren M; Wang Y; Huo D; Lei X; Wang H; Zhai J
    Trials; 2015 Nov; 16():496. PubMed ID: 26530718
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of screening and early detection of impaired fasting glucose tolerance and type 2 diabetes in Canada: a Markov model simulation.
    Mortaz S; Wessman C; Duncan R; Gray R; Badawi A
    Clinicoecon Outcomes Res; 2012; 4():91-7. PubMed ID: 22553425
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical outcomes and cost-effectiveness of strategies for managing people at high risk for diabetes.
    Eddy DM; Schlessinger L; Kahn R
    Ann Intern Med; 2005 Aug; 143(4):251-64. PubMed ID: 16103469
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The association between HbA1c, fasting glucose, 1-hour glucose and 2-hour glucose during an oral glucose tolerance test and cardiovascular disease in individuals with elevated risk for diabetes.
    Lind M; Tuomilehto J; Uusitupa M; Nerman O; Eriksson J; Ilanne-Parikka P; Keinänen-Kiukaanniemi S; Peltonen M; Pivodic A; Lindström J
    PLoS One; 2014; 9(10):e109506. PubMed ID: 25285769
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Screening adults for pre-diabetes and diabetes may be cost-saving.
    Chatterjee R; Narayan KM; Lipscomb J; Phillips LS
    Diabetes Care; 2010 Jul; 33(7):1484-90. PubMed ID: 20587721
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exenatide versus insulin glargine in patients with type 2 diabetes in the UK: a model of long-term clinical and cost outcomes.
    Ray JA; Boye KS; Yurgin N; Valentine WJ; Roze S; McKendrick J; Tucker DM; Foos V; Palmer AJ
    Curr Med Res Opin; 2007 Mar; 23(3):609-22. PubMed ID: 17355742
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-Term Cost-Effectiveness of Insulin Glargine Versus Neutral Protamine Hagedorn Insulin for Type 2 Diabetes in Thailand.
    Permsuwan U; Chaiyakunapruk N; Dilokthornsakul P; Thavorn K; Saokaew S
    Appl Health Econ Health Policy; 2016 Jun; 14(3):281-92. PubMed ID: 26961276
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alternative HbA1c cutoffs to identify high-risk adults for diabetes prevention: a cost-effectiveness perspective.
    Zhuo X; Zhang P; Selvin E; Hoerger TJ; Ackermann RT; Li R; Bullard KM; Gregg EW
    Am J Prev Med; 2012 Apr; 42(4):374-81. PubMed ID: 22424250
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The cost-effectiveness of screening for type 2 diabetes. CDC Diabetes Cost-Effectiveness Study Group, Centers for Disease Control and Prevention.
    JAMA; 1998 Nov; 280(20):1757-63. PubMed ID: 9842951
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of detemir-based basal/bolus therapy versus NPH-based basal/bolus therapy for type 1 diabetes in a UK setting: an economic analysis based on meta-analysis results of four clinical trials.
    Palmer AJ; Roze S; Valentine WJ; Smith I; Wittrup-Jensen KU
    Curr Med Res Opin; 2004 Nov; 20(11):1729-46. PubMed ID: 15537473
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of insulin glargine versus NPH insulin for the treatment of Type 2 diabetes mellitus, modeling the interaction between hypoglycemia and glycemic control in Switzerland.
    Brändle M; Azoulay M; Greiner RA
    Int J Clin Pharmacol Ther; 2011 Mar; 49(3):217-30. PubMed ID: 21329624
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The cost-effectiveness of testing strategies for type 2 diabetes: a modelling study.
    Gillett M; Brennan A; Watson P; Khunti K; Davies M; Mostafa S; Gray LJ
    Health Technol Assess; 2015 May; 19(33):1-80. PubMed ID: 25947106
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.